false
0001734005
0001734005
2026-10-13
2026-10-13
0001734005
dei:FormerAddressMember
2026-10-13
2026-10-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 13, 2026
Niki
BioSolutions, Inc.
(Exact
name of Registrant as Specified in Its Charter)
| Delaware |
|
001-38764 |
|
42-3265309 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
| 116
Village Boulevard, Suite 200, Princeton, NJ 08540 |
| (Address
of Principal Executive Offices, including zip code) |
Registrant’s
Telephone Number, Including Area Code: 609-951-2222
Aptorum
Group Limited
17
Hanover Square
London
W1S 1BN, United Kingdom
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common
stock, par value $0.0001 per share |
|
NIKI |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On
October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”),
appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing
as of September 1, 2026, unless terminated sooner by either party.
Prior
to his appointment, Mr. Freeburg, age 59, was the Managing Member of Cambridge Accounting Group, LLC from 2014 to September 2017 and
April 2023 to August 2026. Mr. Freeburg was previously employed by Interpace Biosciences, Inc. (NASDAQ: IDXG) and served as the company’s
Chief Accounting Officer from October 2017 through January 2021, and as Chief Financial Officer, Secretary and Treasurer from February
2021 through March 2023. From 2009 to 2014, Mr. Freeburg served as the Director of SEC Reporting and Accounting Policies for Coach, Inc.,
which was the predecessor company to Tapestry, Inc. (NYSE: TPR). From 2006 to 2008, Mr. Freeburg served as the Director of External Reporting
of Scholastic Corporation (NASDAQ: SCHL). Mr. Freeburg is a Certified Public Accountant and earned his Bachelor of Science degree in
Public Accounting from Long Island University.
Pursuant
to the terms of the Employment Agreement between the Company and Mr. Freeburg, Mr. Freeburg will receive a base salary of $250,000, which
shall be paid monthly although $25,000 shall be deferred until such time as the Company receives certain funding, as set forth in the
Employment Agreement; his base salary shall increase to $275,000, upon the Company’s receipt of additional funding. Mr. Freeburg
is also entitled to an annual bonus in an amount up to 50% of his base salary. Mr. Freeburg shall also receive 50,000 stock options,
with an exercise price equal to $8.83 per share, with an agreed upon vesting schedule. Either party can terminate the agreement upon
45 days’ notice prior to the end of the then current term, and the Company may remove Mr. Freeburg at any time for cause and to the extent
permitted by applicable law; the Employment Agreement specifies the benefits and compensation for which Mr. Freeburg is entitled based
upon the reason for such termination. Mr. Freeburg is also entitled to specified benefits and severance payments.
There
are no family relationships between Mr. Freeburg and any director or executive officer of the Company, and there are no arrangements
or understandings between Mr. Freeburg and any other person pursuant to which he was selected as an officer of the Company. Mr. Freeburg
has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The
foregoing summary of the Employment Agreement is qualified in its entirety by reference to said agreement, which is filed as Exhibit
10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit |
|
Description |
| 10.1 |
|
Employment Agreement with Thomas Freeburg |
| 104 |
|
Cover
Page Interactive Data File, formatted in Inline XBRL |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
October 13, 2026
| |
NIKI BIOSOLUTIONS, INC. |
| |
|
|
| |
By: |
/s/
Ian Huen |
| |
|
Ian
Huen |
| |
|
Chief
Executive Officer |
